Volume 32 -Issue S5 -2021 S465respectively. Among patients using CT with maintenance treatment, maintenance ET (54.96%) and maintenance CT (38.34%) were the most commonly used therapies.Maintenance ET had longer median PFS than maintenance CT [18.99 (95%CI,) months].Conclusions: This real-world study indicated CT with maintenance treatment was the most common first-line treatment for HR positive ABC patients. Of note, first-line maintenance ET was associated with better PFS than maintenance CT.

No abstract

Background: The real-world intracranial efficacy data of ceritinib at a dose of 450mg QD are still unavailable, thus this study aims to analyze the intracranial efficacy of ceritinib (450mg QD) in ALK-rearrangement NSCLC patients in China.Methods: The intracranial and whole body efficacies [objective response rate (ORR) and disease control rate (DCR)] were respectively evaluated according to the Response Assessment in Neuro-Oncology (RANO) and Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) standards, along with progression-free survival (PFS)/survival time and adverse events (AEs) obtained through follow-ups. abstracts Annals of OncologyVolume 31 -Issue S6 -2020 S1395Clinical trial identification: NCT03389087.

No abstract

Conclusions: Toripalimab in combination with paclitaxel as second-line therapy for advanced GC showed tolerant toxicity and preliminary clinical efficacy. The conclusion should be validated in more pts consecutively.Clinical trial identification: NCT04563975.